Ampicillin

Ampicillin is a broad-spectrum beta-lactam antibiotic belonging to the aminopenicillin class of the penicillin family, widely utilized in clinical medicine to prevent and treat a diverse array of bacterial infections by inhibiting bacterial cell wall synthesis. Since its introduction in 1961, it has remained a foundational antimicrobial agent on the World Health Organization's List of Essential Medicines, notable for its efficacy against both Gram-positive and select Gram-negative pathogens.

Medical Uses

Ampicillin is indicated for the treatment of various bacterial infections, including respiratory tract infections (such as pneumonia and bronchitis), urinary tract infections, meningitis, endocarditis, and gastrointestinal infections caused by Salmonella species. It is particularly recognized as a first-line treatment for infections caused by Listeria monocytogenes, Enterococcus faecalis, and susceptible strains of Streptococcus pneumoniae and Haemophilus influenzae.

In obstetric and neonatal care, intravenous ampicillin is routinely administered as prophylaxis to pregnant women who test positive for Group B Streptococcus (GBS) to prevent early-onset neonatal sepsis. Additionally, it is used prophylactically in certain surgical procedures and for patients with specific cardiac conditions to prevent bacterial endocarditis.

Mechanism of Action

As a beta-lactam antibiotic, ampicillin exerts its bactericidal effect by interfering with the synthesis of the bacterial cell wall. The drug contains a beta-lactam ring that structurally mimics the D-alanyl-D-alanine terminus of the peptidoglycan precursor. Ampicillin binds covalently to and inhibits penicillin-binding proteins (PBPs), which are transpeptidase enzymes located on the inner membrane of the bacterial cell wall. This inhibition prevents the cross-linking of peptidoglycan chains, a crucial step for maintaining the structural integrity of the cell wall. The resulting weakened cell wall leads to osmotic instability, cell lysis, and ultimately bacterial death.

Pharmacokinetics

Ampicillin can be administered orally, intravenously, or intramuscularly. Oral absorption is variable and can be significantly decreased by the presence of food in the gastrointestinal tract. Once absorbed, the drug is widely distributed throughout body tissues and fluids, including the lungs, liver, and bile. While it penetrates the cerebrospinal fluid (CSF) poorly under normal conditions, CSF concentrations increase significantly when the meninges are inflamed, making it effective for treating bacterial meningitis.

The drug undergoes minimal hepatic metabolism, with approximately 20% metabolized into inactive penicilloic acid. The majority of an administered dose is excreted unchanged in the urine via glomerular filtration and active tubular secretion. The elimination half-life in adults with normal renal function is approximately 1 to 1.5 hours, necessitating dose adjustments in patients with renal impairment to prevent toxicity.

Adverse Effects

The most common adverse effects associated with ampicillin are gastrointestinal disturbances, including nausea, vomiting, and diarrhea. A more severe gastrointestinal complication is Clostridioides difficile-associated diarrhea (pseudomembranous colitis), which can occur due to the disruption of normal intestinal flora.

Hypersensitivity reactions are a significant concern, ranging from mild maculopapular rashes to life-threatening anaphylaxis. A non-allergic, characteristic maculopapular rash is highly prevalent when ampicillin is administered to patients with infectious mononucleosis (caused by the Epstein-Barr virus) or cytomegalovirus infections. Other rare but serious adverse effects include interstitial nephritis, hepatotoxicity, and central nervous system toxicity, such as seizures, particularly when high doses are administered to patients with compromised renal function.

Contraindications and Precautions

Ampicillin is strictly contraindicated in individuals with a known history of severe hypersensitivity or anaphylactic reactions to penicillins or other beta-lactam antibiotics, including cephalosporins and carbapenems. Caution is advised when prescribing the drug to patients with a history of asthma, eczema, or hay fever, as they may have a higher predisposition to allergic reactions.

Patients with infectious mononucleosis should generally avoid ampicillin due to the exceptionally high risk of developing a severe skin rash. Furthermore, because the drug is primarily cleared by the kidneys, dosage regimens must be carefully adjusted for patients with moderate to severe renal impairment to avoid drug accumulation and subsequent neurotoxicity.

Drug Interactions

Ampicillin interacts with several medications, which can alter its efficacy or toxicity profile. Probenecid, a uricosuric agent, competitively inhibits the renal tubular secretion of ampicillin, thereby increasing its serum concentration and prolonging its half-life. This interaction is sometimes utilized therapeutically to enhance antibiotic levels.

Concurrent use of ampicillin and allopurinol significantly increases the incidence of skin rashes. There is also evidence suggesting that broad-spectrum antibiotics like ampicillin may reduce the enterohepatic recirculation of estrogens, potentially decreasing the efficacy of oral contraceptives, although the clinical significance of this interaction remains debated. Additionally, combining ampicillin with bacteriostatic antibiotics, such as tetracyclines or macrolides, may result in antagonistic effects, as bacteriostatic agents inhibit the active cell division required for beta-lactams to exert their bactericidal action.

Bacterial Resistance

Bacterial resistance to ampicillin is a widespread clinical challenge. The primary mechanism of resistance is the production of beta-lactamases, enzymes synthesized by many bacterial strains (such as Staphylococcus aureus, Haemophilus influenzae, and Escherichia coli) that hydrolyze the beta-lactam ring, rendering the antibiotic inactive. Alterations in penicillin-binding proteins and decreased outer membrane permeability in Gram-negative bacteria also contribute to resistance.

To overcome beta-lactamase-mediated resistance, ampicillin is frequently formulated in combination with a beta-lactamase inhibitor, most notably sulbactam (as ampicillin/sulbactam). Sulbactam possesses minimal intrinsic antibacterial activity but irreversibly binds to and inhibits beta-lactamases, thereby protecting ampicillin from enzymatic degradation and restoring its efficacy against resistant bacterial populations.

History

Ampicillin was discovered in 1961 by researchers at the Beecham Group in the United Kingdom. Prior to its development, available penicillins, such as penicillin G and penicillin V, were primarily effective only against Gram-positive bacteria. The addition of an amino group to the benzylpenicillin structure allowed ampicillin to penetrate the outer membrane of Gram-negative bacteria, making it the first broad-spectrum penicillin. Its introduction marked a significant milestone in antimicrobial therapy, vastly expanding the range of treatable infections and establishing a structural template for the subsequent development of other aminopenicillins, such as amoxicillin.